An evaluation of Pf-HRP2 RDT (CareStartTM) using samples from suspected malaria cases aged 1–81 years using PCR as the reference, reports sensitivities ranging from 71% [56], 72% to 75% [57] as compared to 87% in the current study. The gene discussed is HDGFL2; the disease is malaria.